Commonwealth Equity Services LLC Lowers Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Commonwealth Equity Services LLC reduced its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 7.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,319 shares of the company’s stock after selling 4,582 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Recursion Pharmaceuticals were worth $367,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Swiss National Bank lifted its holdings in shares of Recursion Pharmaceuticals by 36.3% in the 4th quarter. Swiss National Bank now owns 486,700 shares of the company’s stock worth $3,290,000 after acquiring an additional 129,600 shares during the last quarter. Farther Finance Advisors LLC boosted its position in Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock valued at $52,000 after acquiring an additional 1,353 shares in the last quarter. HighTower Advisors LLC raised its holdings in Recursion Pharmaceuticals by 408.5% in the fourth quarter. HighTower Advisors LLC now owns 122,770 shares of the company’s stock worth $830,000 after purchasing an additional 98,626 shares in the last quarter. Prosperity Wealth Management Inc. purchased a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $257,000. Finally, Daiwa Securities Group Inc. grew its stake in shares of Recursion Pharmaceuticals by 28.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company’s stock worth $69,000 after buying an additional 2,235 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Trading Down 11.9 %

RXRX stock opened at $4.24 on Monday. The firm has a fifty day moving average price of $7.22 and a 200 day moving average price of $6.95. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $4.06 and a fifty-two week high of $12.36. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm has a market cap of $1.70 billion, a PE ratio of -2.77 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same quarter in the prior year, the business earned ($0.42) earnings per share. The firm’s quarterly revenue was down 57.8% compared to the same quarter last year. Sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Leerink Partners decreased their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Friday, February 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, KeyCorp lowered their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $8.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.